- Home
- OP vs MRKR Comparison
OP vs MRKR Comparison
Compare OP & MRKR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OP
- MRKR
- Stock Information
- Founded
- OP 2021
- MRKR N/A
- Country
- OP Greece
- MRKR United States
- Employees
- OP N/A
- MRKR N/A
- Industry
- OP
- MRKR Biotechnology: Pharmaceutical Preparations
- Sector
- OP
- MRKR Health Care
- Exchange
- OP Nasdaq
- MRKR Nasdaq
- Market Cap
- OP 14.3M
- MRKR 11.6M
- IPO Year
- OP N/A
- MRKR N/A
- Fundamental
- Price
- OP $1.27
- MRKR $0.96
- Analyst Decision
- OP
- MRKR Strong Buy
- Analyst Count
- OP 0
- MRKR 3
- Target Price
- OP N/A
- MRKR $13.17
- AVG Volume (30 Days)
- OP 701.6K
- MRKR 2.7M
- Earning Date
- OP 08-08-2025
- MRKR 11-13-2025
- Dividend Yield
- OP N/A
- MRKR N/A
- EPS Growth
- OP N/A
- MRKR N/A
- EPS
- OP N/A
- MRKR N/A
- Revenue
- OP $19,435,000.00
- MRKR $5,388,071.00
- Revenue This Year
- OP N/A
- MRKR N/A
- Revenue Next Year
- OP N/A
- MRKR $9.35
- P/E Ratio
- OP N/A
- MRKR N/A
- Revenue Growth
- OP N/A
- MRKR 44.55
- 52 Week Low
- OP $1.07
- MRKR $0.81
- 52 Week High
- OP $79.25
- MRKR $5.95
- Technical
- Relative Strength Index (RSI)
- OP 32.72
- MRKR 42.77
- Support Level
- OP $1.19
- MRKR $0.91
- Resistance Level
- OP $1.21
- MRKR $1.02
- Average True Range (ATR)
- OP 0.09
- MRKR 0.06
- MACD
- OP 0.64
- MRKR 0.02
- Stochastic Oscillator
- OP 52.08
- MRKR 68.42
About OP OceanPal Inc.
OceanPal Inc is a provider of shipping transportation services. It specializes in the ownership of vessels. Each of its vessels is owned through a separate wholly-owned subsidiary. The company includes Dry Bulk segment and Tanker segment. Majority of revenue is Dry Bulk segment.
About MRKR Marker Therapeutics Inc.
Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets.